Abstracts

701 BRIGHTPLEX® TCE AND BRIGHTPLEX® MDSC ASSAYS COMBINATION IMPROVES ADVANCED NSCLC PATIENTS’ STRATIFICATION UNDER ANTI-PD1/L1 IMMUNOTHERAPY IN THE PIONEER PROJECT

Lamia Ghazali, 1Marcellin Landri, 1Florence Monville, 1Vanina Leca, 1Théo Vasse, 1Chafik Hamdadi, 1Margaux Mercadal, 1Laurent Vanhille, 1Alboukadel Kasassbara, 1Thomas Sbarrato, 1Maryannick Le Ray, 1Marie Rousmieux, 2Richard Malkoun, 2Noémie Resseguier, 2Arnaud Boyer, 2Clarisse Audigier-Vallette, 2Stephanie Martinez, 2Hervé Pegliasco, 2Patrice Ray, 2Lionel Falcher, 2Antoine Sère, 2Nicolas Cloarec, 2Louisiane Lebas, 2Stéphane Hominal, 2Patricia Barra, 2Sarath Zahi, 2Ahmed Frihka, 2Pierre Boyo, 2Lilian Laborde, 2Julien Mazières, 2Virginie Martin, 2Julien Mazières, 2Maurice Pérol, 3Laurent Grelletier, 3Fabrice Barlesi, 3Jacques Fischet, 4Veracete, Marseille, France; 5APHM, Marseille, France; 6Aix Marseille Université, Marseille, France; 6Aix Marseille Université, Marseille, France; 6Aix Marseille Université, Marseille, France; 6Institut Paoli Calmettes and sponsored by APHM. Drug supply is funded by AstraZeneca. Special thanks to patients and families.

Methods

Patients were mainly male (60%), smokers (98.33%), <70yrs (71.66%), median PFS was 3.9 months. Across the 60 groups: log-rank test. Samples correlation to survival

Abstract 701 Table 1 Advanced NSCLC stratification according to tumor infiltration by T-lymphocytes, PMN-MDSC+granulocytes and correlation to survival


http://jitc.bmj.com; on November 16, 2022. Protected by copyright.